Moderna's Flu/COVID Vaccine Prospects Are Undervalued By The Market

Jelena Stanojkovic/iStock via Getty Images At a Glance Delving into Moderna's (NASDAQ:MRNA) trajectory, my earlier analysis shed light on its eclectic project range. This spectrum spans from oncology to infectious diseases, with notable breakthroughs in RSV and flu vaccines. Moderna has since leaped forward, especially with mRNA-1083. This vaccine, both innovative and dual-purpose, targets COVID-19 and flu. It's now in Phase 3, with approval expected in 2025. However, it's not all smooth sailing. The pa ...